News White House signs pricing deals with nine more pharmas Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.
News Lilly, Regeneron among firms chosen for FDA fast plant pilot Eli Lilly, Regeneron, and five other drugmakers will take part in an FDA pilot designed to make it quicker and easier to set up manufacturing plants.
News Cancer risk scuppers Kyowa Kirin's autoimmune disease drug Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.
News Kura scores FDA okay for rival to Syndax's leukaemia drug Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.
Patients How pharma is tackling new direct-to-patient programmes At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
News Spain agrees to reimburse Orchard's gene therapy Libmeldy Spain has agreed to reimburse Orchard Therapeutics' ex vivo gene therapy for the rare childhood disease metachromatic leukodystrophy.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.